Independent evolution of hypervariable regions of HIV-1 gp120: V4 as a swarm of N-linked glycosylation variants

AIDS Research and Human Retroviruses

Volumn 24, Issue 1, 2008, Pages 106-113

  Castro, Erika ^a   Bélair, Manon ^b   Rizzardi, Gian Paolo ^c   Bart, Pierre A ^a   Pantaleo, Giuseppe ^a   Graziosi, Cecilia ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITÉ LAVAL   (Canada)

^c MOLMED S P A   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120;

AMINO ACID SUBSTITUTION; ARTICLE; CLADISTICS; CLINICAL ASSESSMENT; CONFORMATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GLYCOSYLATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGLOBULIN VARIABLE REGION; MOLECULAR CLONING; MOLECULAR EVOLUTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS ISOLATION;

ACUTE DISEASE; AMINO ACID SEQUENCE; ANTI-HIV AGENTS; CHRONIC DISEASE; EVOLUTION, MOLECULAR; GLYCOSYLATION; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; INDEL MUTATION; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PHYLOGENY; POLYMORPHISM, GENETIC;

EID: 38149080706     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0139     Document Type: Article

References (22)

1. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, and Detours V: Evolutionary and immunological implications of contemporary HIV variation. Br Med Bull 2001;58:19-42.
2. Geyer H, Holschbach C, Hunsmann G, and Schneider J: Carbohydrates of human immunodeficiency virus. J Biol Chem 1988;263:11760-11767.
3. Scanlan CN, Offer J, Zitzmann N, and Dwek RA: Exploiting the defensive sugars of HIV-1 for drug and vaccine design. Nature 2007;446:1038-1045.
4. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak Ma, Hahn BH, Kwong PD, and Shaw GM: Antibody neutralization and escape by HIV-1. Nature 2003;422(6929):307-312.
5. Meunier JC, Fournillier A, Choukhi A, Cahour A, Coquerel L, Dubuisson J, and Wychowski C: Analysis of the glycosylation sites of hepatitis C virus (HCV) glycoprotein E1 and the influence of E1 glycans on the formation of the HCV glycoprotein complex. J Gen Virol 1999;80:887-896.
6. Ren X, Sodroski J, and Yang X: An unrelated monoclonal antibody neutralizes human immunodeficiency virus type 1 by binding to an artificial epitope engineered in a functionally neutral region of the viral envelope glycoproteins. J Virol 2005;79(9):5616-5624.
7. Poon AF, Lewis FI, Kosakovsky Pond SL, and Frost SD: Evolutionary interactions between N-linked glycosylation sites in the HIV-1 envelope. PLoS Comput Biol 2007;3(1):e11.
8. Bruce C, Clegg C, Featherstone , Smith J, Biryahawaho B, Downing R, and Oram J: Presence of multiple genetic subtypes of human immunodeficiency virus type 1 proviruses in Uganda. AIDS Res Hum Retroviruses 1994;10(11):1543-1550.
9. Rong R, Gnanakaran S, Decker JM, Bibollet-Rucke F, Taylor J, Sfakianos JN, Mokili JL, Muldoon M, Mulenga J, Allen S, Hahn BH, Shaw GM, Blackwell JL, Korber BT, Hunter E, and Derdeyn CA: Unique mutational patterns in the envelope {alpha}2 amphipathic helix and acquisition of length in gp120 hyper-variable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1. J Virol 2007;81(11):5658-5668.
10. Bures R, Gaitan A, Zhu T, Graziosi C, McGrath KM, Tartaglia J, Caudrelier P, El Habib R, Klein M, Lazzarin A, Stablein D, Deers M, Corey L, Greenberg ML, Schwartz DH, and Montefiori DC: Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2000;16(18):2019-2035.
11. Pilgrim AK, Pantaleo G, Cohen OJ, Fink LM; Zhou JY, Zhou JT, Bolognesi DP, Fauci AS, and Montefiori DC: Neutralizing antibody response to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis 1997;176:923-932.
12. Bart PA, Rizzardi GP, Tambussi G, Chave JP, Chapuis AG, Graziosi C, Corpataux JM, Halkic N, Meuwly JY, Munoz M, Meylan P, Spreen W, McDade H, Yerly S, Perrin L, Lazzarin A, and Pantaleo G: Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy. AIDS 2000;14(13):1887-1897.
13. Rizzardi GP, Tambussi G, Bart PA, Chapuis AG, Lazzarin A, and Pantaleo G: Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count. AIDS 2000;14(15):2257-2263.
14. CDC Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults. MMWR Recomm Rep 1992;41(RR-17):1-19.
15. Ratner L, Haseltine W, Patarca R, Livak KJ, Starcich B, Josephs SF, Doran ER, Rafalski JA, Whitehorn EA, Baumeister K, et al.: Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 1985;313(6000):277-284.
16. Marshall RD: The nature and metabolism of the carbohydrate-peptide linkages of glycoproteins. Biochem Soc Symp 1974;40:17-26.
17. Kasturi L, Chen H, and Shakin-Eshleman SH: Regulation of N-linked core glycosylation: Use of a site-directed mutagenesis approach to identify Asn-Xaa-Ser/Thr sequons that are poor oligosaccharide acceptors. Biochem J 1997;323(2):415-419.
18. Mellquist JL, Kasturi L, Spitalnik SL, and Shakin-Eshleman SH: The amino acid following an asn-X-Ser/Thr sequon is an important determinant of N-linked core glycosylation efficiency. Biochemistry 1998;37(19):6833-6837.
19. Zhang M, Gaschen B, Blay W, Foley B, Haigwood N, Kuiken C, and Korber B: Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology 2004;14(12):1229-1246.
20. Gnanakaran S, Lang D, Daniels M, Bhattacharya T, Derdeyn C, and Korber B: Clade-specific differences between human immunodeficiency virus type 1 clades B and C: Diversity and correlations in C3-V4 regions of gp120. J Virol 2007;81(9):4886-4891.
21. Clevestig P, Pramanik L, Leitner T, and Ehrnst A: CCR5 use by human immunodeficiency virus type 1 is associated closely with the gp120 V3 loop N-linked glycosylation site. J Gen Virol 2006;87(Pt. 3):607-612.
22. Cummings CJ and Zpghbi HY: Trinucleotide repeats: Mechanism and pathophysiology. Annu Rev Genomics Hum Genet 2000;1:281-328.